NCT02658734已完成4 期
A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 13
- 主要终点
- Severity of Adverse Events
研究概览
简要总结
This is a Phase IV, single-arm, multicenter, open-label clinical trial designed to assess the safety of trastuzumab emtansine in Indian patients with HER2-positive unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior treatment with trastuzumab and a taxane.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prospectively confirmed HER2-positive (i.e., IHC 3+ or IHC 2+ and gene amplified by fluorescence in situ hybridization [FISH] positive) as assessed on primary tumor and/or metastatic site
- •Documented progression of unresectable, locally advanced, or mBC, determined by the investigator
- •Left ventricular ejection fraction (LVEF) >/= 50% by echocardiogram (ECHO)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •A negative serum Beta-Human Chorionic Gonadotropin (Beta-HCG) test for women of childbearing potential (premenopausal or not meeting the definition of postmenopausal i.e. >/= 12 months of amenorrhea), and women who have not undergone surgical sterilization (i.e., absence of ovaries and/or uterus)
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate non-hormonal methods of contraception, including at least one method with a failure rate of <1% per year, during the treatment period and for at least 7 months after the last dose of study drug
- •For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm. With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 7 months plus 90 days (a spermatogenesis cycle) after the last dose of study drug. Men must refrain from donating sperm during this same period. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 7 months after the last dose of study drug.
排除标准
- •Prior treatment with trastuzumab emtansine
- •Prior treatment with lapatinib or lapatinib with capecitabine or non-comparable biologic or biosimilar of trastuzumab
- •Peripheral neuropathy of Grade >/= 3 per the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE [version 4.03])
- •History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a similar curative outcome as those mentioned above
- •History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to enrollment except hormone therapy, which can be given up to 7 days prior to enrollment; recovery of treatment-related toxicity consistent with other eligibility criteria
- •History of exposure to cumulative doses of anthracyclines, as defined in the protocol
- •History of radiation therapy within 14 days of enrollment
- •Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as a history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) before enrollment
- •CNS only disease
- •History of a decrease in LVEF to < 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment
- •History of symptomatic chronic heart failure (New York Heart Association [NYHA] Classes II-IV) or serious cardiac arrhythmia requiring treatment
- •History of myocardial infarction or unstable angina within 6 months of enrollment
- •Current dyspnea at rest due to complications of advanced malignancy or requirement for continuous oxygen therapy
- •Current severe, uncontrolled systemic disease
- •Pregnancy or lactation
- •Concurrent, serious, uncontrolled infections or current known infection with human immunodeficiency virus (HIV) or active hepatitis B and/or hepatitis C. For patients who are known carriers of hepatitis B virus (HBV), active hepatitis B infection must be ruled out, based on negative serologic testing and/or determination of HBV DNA viral load per local guidelines
- •Presence of conditions that could affect gastrointestinal absorption: malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis
- •History of intolerance (such as Grade 3-4 infusion reaction) or known hypersensitivity to trastuzumab or murine proteins or any component of the product
- •Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
研究组 & 干预措施
Trastuzumab emtansine
Experimental
干预措施: Trastuzumab emtansine (Drug)
结局指标
主要结局
Severity of Adverse Events
时间窗: From cycle 1 up to approximately 3 years
Adverse events (AEs) grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
Percentage of Participants With Adverse Events
时间窗: From cycle 1 up to approximately 3 years
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events.
次要结局
- Severity of SAEs as Per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03(From cycle 1 up to approximately 3 years)
- Percentage of Participants With Adverse Events Leading to Discontinuation of Study Medication(From cycle 1 up to approximately 3 years)
- Percentage of Participants With Adverse Events Leading to Interruption of Study Medication(From cycle 1 up to approximately 3 years)
- Exposure to Study Drug(From cycle 1 up to approximately 3 years)
- Percentage of Participants With Drug-Induced Liver Injury Meeting Hy's Law Criteria(From cycle 1 up to approximately 3 years)
- Change in Left Ventricular Ejection Fraction (LVEF) as Measured by Echocardiogram(From baseline to every three cycles of treatment up to Cycle 39 Day 1, and at the 2-days post-treatment, safety follow-up visits 1 and 3)
- Overall Response Rate (ORR)(From cycle 1 up to approximately 3 years)
- Percentage of Participants With Serious Adverse Events (SAEs)(From cycle 1 up to approximately 3 years)
- Percentage of Participants With Non-Serious Adverse Events of Special Interest(From cycle 1 up to approximately 3 years)
- Laboratory Results Abnormalities(From cycle 1 up to approximately 3 years)
- Percentage of Participants With Adverse Events Leading to Modification of Study Medication(From cycle 1 up to approximately 3 years)
- Percentage of Participants With Congestive Heart Failure(From cycle 1 up to approximately 3 years)
- Progression-Free Survival (PFS)(From cycle 1 up to approximately 3 years)
- Overall Survival (OS)(From cycle 1 up to approximately 3 years)
研究者
研究点 (13)
Loading locations...
相似试验
已完成
4 期
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)Juvenile Idiopathic ArthritisNCT03301883Hoffmann-La Roche62
已完成
4 期
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)Muscular Atrophy, SpinalNCT05073133Novartis Pharmaceuticals16
招募中
4 期
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyMuscular Atrophy, SpinalNCT05861999Hoffmann-La Roche28
招募中
4 期
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyMuscular Atrophy, SpinalNCT05861986Hoffmann-La Roche28
已完成
4 期
Brilinta DaYu StudyAcute Coronary SyndromeNCT01870921AstraZeneca2,004